Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Morgan Thakore

Dermatology Augusta, GA Medical Doctor

NPI 1770875130 CMS profile 1267359

1111 Garredd Blvd, Augusta, GA 30909

Open in the dashboard

General payments

$6,188

275 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morgan Thakore of Augusta, GA is reported in the CMS Open Payments database as having received $6,188 across 275 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,605 79
2024 General $1,295 56
2023 General $1,144 45
2022 General $696 32
2021 General $411 18
2020 General $204 11
2019 General $832 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morgan Thakore
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Morgan Thakore were reported at $1,605. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Morgan Thakore Dermatology median Middle half National median
2019 $832 $454 $129–$1,240 $163
2020 $204 $235 $81–$756 $114
2021 $411 $377 $108–$1,108 $132
2022 $696 $514 $143–$1,391 $149
2023 $1,144 $607 $159–$1,674 $160
2024 $1,295 $751 $204–$1,903 $164
2025 $1,605 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,226 61 payments
  2. Regeneron Healthcare Solutions, Inc. $1,034 35 payments
  3. Janssen Biotech, Inc. $495 24 payments
  4. Lilly USA, LLC $491 25 payments
  5. Amgen Inc. $476 21 payments
  6. Novartis Pharmaceuticals Corporation $391 19 payments
  7. Pfizer Inc. $390 22 payments
  8. Sun Pharmaceutical Industries Inc. $254 10 payments
  9. UCB, Inc. $234 10 payments
  10. Genzyme Corporation $188 9 payments
  11. Other $1,010 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,931 269 payments
  2. Education $257 6 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $728 23 payments
  2. SKYRIZI Immunology $693 34 payments
  3. Otezla $476 21 payments
  4. TREMFYA $449 22 payments
  5. TALTZ $396 21 payments
  6. SKYRIZI Immunology $322 18 payments
  7. CIBINQO $320 17 payments
  8. DUPIXENT Immunology And Inflammation $306 12 payments
  9. LITFULO $290 15 payments
  10. DUPIXENT Immunology $265 11 payments
  11. Other $2,973 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

434

Median for Dermatology: 534

Drug cost

$710,464

Median for Dermatology: $67,151

Branded share of claims

18.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 12 $266,559
Humira(Cf) Pen Adalimumab Brand 19 $236,196
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $107,439
Dupixent Pen Dupilumab Brand 24 $87,002
Tacrolimus Generic 23 $3,975
Clobetasol Propionate Generic 51 $1,950
Tretinoin Generic 18 $1,598
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 13 $965
Fluorouracil Generic 11 $789
Ketoconazole Generic 77 $777

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$15,372

Medicare's payments for the services billed

Medicare patients

157

Average age 72

Services billed

383

93 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 29%
Diabetes 28%
Chronic kidney disease 22%
Depression 22%
Atrial fibrillation 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $257
  • GENZYME CORPORATION $15
$271 24 —
SKYRIZI
  • AbbVie, Inc. $196
$196 12 —
Otezla
  • Amgen Inc. $181
$181 — —
TREMFYA
  • Janssen Biotech, Inc. $131
$131 — —
TALTZ
  • Lilly USA, LLC $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record